IRADIMED CORP (IRMD) IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
IRadimed Corporation NASDAQ:IRMD Healthcare · Medical - Devices
Mkt Cap $1.1B
Div Yield 1.47%
Pre Pre-market +0.00% $86.31
Close $86.31 0.00% Now $86.31 PM VOL 204 $ Vol ≈ $18K RVOL 0.63x
Close $86.31 +0.90% AH $86.31 +0.00% vs close
Mkt Cap $1.1B
PM VOL 204 sh
$ Vol ≈$18K
RVOL 0.63×
Div Yield 1.47%
Press Release ● Major ⚠ 2
IRADIMED CORPORATION Reports Third Quarter 2026 Financial Results
IRADIMED reported record Q3 2026 revenue of $24.2 million, up 14% year-over-year, with GAAP diluted EPS of $0.51 (+17% YoY) and non-GAAP EPS of $0.55.
Bookings set records on the 3870 MR IV pump launch, with domestic pump channel bookings up 45% YoY and over 70% of pump bookings in the higher-capacity 'quad stack' configuration; gross margin improved sequentially to 76%.
Management guided Q4 revenue to $25.0-$26.5 million, reaching a $100 million annual run rate, but narrowed full-year guidance ranges, trimming the top end of revenue and EPS.
The board declared a regular $0.20 quarterly dividend payable November 27, 2026; the company holds $63.3 million in cash with no debt.
• 10d ago AI analysis › Press Release
IRADIMED CORPORATION to Hold Third Quarter 2026 Financial Results Conference Call on October 30, 2026
IRadimed will release its third quarter 2026 financial results before market open on Friday, October 30, 2026.
Management will host a conference call the same day at 11:00 a.m. Eastern Time, with registration and a live webcast available via the company's investor events page.
The release contains no financial results or guidance and is purely a scheduling notice ahead of the earnings print.
• 17d ago AI analysis › Press Release
IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference
Iradimed announced it will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026, at the Metropolitan Club in New York.
CFO Jack Glenn will host one-on-one meetings between company management and investors at the event.
The release contains no new financial or operational information; it is a routine investor-calendar notice with standard company background.
• 1mo ago AI analysis › Press Release ⚠ 3
IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
Iradimed reported Q2 revenue of $20.5 million, up 0.5% year-over-year, while GAAP EPS fell 9% to $0.41 due to costs associated with ramping its new 3870 MR IV pump.
Gross margins contracted to 74% from 78% in the prior year period, though management noted record domestic monitor bookings and reaffirmed full-year guidance.
The board declared a quarterly cash dividend of $0.20 per share, payable August 28, and maintained FY2026 revenue guidance of $91.0 million to $96.0 million.
• 3mo ago AI analysis › Press Release
IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026
IRADIMED CORPORATION announced that it will release its second quarter 2026 financial results before the market opens on Friday, July 31, 2026.
Management will host a conference call the same day at 11:00 a.m. Eastern Time to discuss the results, with registration available online and a webcast provided on the company's website.
The company specializes in MRI-compatible medical devices, including the MRidium infusion pump systems and the 3880 vital signs monitoring system.
• 3mo ago AI analysis › Press Release
IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Iradimed Corporation announced that CEO Roger Susi and CFO Jack Glenn will attend the Goldman Sachs 47th Annual Global Healthcare Conference.
The event is scheduled for June 8–10, 2026, at the Loews Miami Beach Hotel in Miami Beach, Florida.
Investors may contact their Goldman Sachs representatives to schedule one-on-one meetings with Iradimed management during the conference.
• 5mo ago AI analysis › Press Release ● Major
IRADIMED CORPORATION Reports First Quarter 2026 Financial Results
Iradimed reported Q1 2026 revenue of $22.0 million, up 13% year-over-year, driven by double-digit growth in its MRI-compatible device portfolio.
GAAP diluted EPS rose 22% to $0.45, while operating income increased 33% to $7.2 million, supported by disciplined expense management.
The company declared a $0.20 per share dividend and reaffirmed full-year revenue guidance of $91.0 million to $96.0 million following the commercial launch of its next-generation 3870 infusion pump.
• 6mo ago AI analysis › 
